Physician profile
Jennifer Meyer
NPI 1588035117
$9,870.54
in general payments reported to CMS, 2019-2025
31 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,557 · 2022: $1,938 · 2023: $2,025 · 2024: $2,249 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,328 · Education: $46.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,328.28 |
| Education | $46.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,811.32 | 2021-2025 | |
| Gilead Sciences, INC. | $1,264.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,028.27 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $841.22 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $696.92 | 2021-2025 | Tremfya, Stelara, Simponi |
| Celgene Corporation | $635.45 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $416.99 | 2023-2025 | Omvoh |
| Pfizer INC. | $401.28 | 2021-2025 | |
| Genzyme Corporation | $288.92 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $259.25 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $193.49 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $128.62 | 2021-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $112.05 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $109.49 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $105.05 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $82.72 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $72.58 | 2021-2024 | Rebyota |
| Nestle Healthcare Nutrition INC. | $67.20 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $62.75 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $47.31 | 2021-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $38.41 | 2023-2024 | Dificid |
| Celltrion USA INC. | $33.20 | 2023 | Yuflyma |
| Echosens North America, INC. | $32.22 | 2024 | Fibroscan |
| Sandoz INC. | $26.19 | 2025 | Hyrimoz |
| Biocon Biologics INC | $20.86 | 2024 | Hulio |
| Redhill Biopharma INC. | $17.07 | 2023 | |
| Novo Nordisk INC | $16.52 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $16.06 | 2021 | |
| Organon LLC | $15.48 | 2023 | Renflexis |
| Orphalan INC | $14.39 | 2025 | Cuvrior |
| Fresenius Kabi USA, LLC | $14.37 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.